Jazz Pharmaceuticals (JAZZ) Depreciation & Amortization (CF) (2010 - 2026)

Jazz Pharmaceuticals' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $9.1 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 12.5% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $40.3 million (up 13.62% YoY), while the FY2025 annual figure was $41.6 million, up 27.12% from the prior year.
• Depreciation & Amortization (CF) was $9.1 million for Q1 2026 at Jazz Pharmaceuticals, down from $9.4 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $11.9 million in Q2 2025 to a low of $7.3 million in Q4 2022.
• Historically, Depreciation & Amortization (CF) has averaged $8.5 million across 5 years, with a median of $7.7 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) surged 59.38% in 2022, then dropped 12.5% in 2026.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $7.3 million in 2022, then increased by 4.14% to $7.6 million in 2023, then rose by 24.4% to $9.5 million in 2024, then slipped by 0.91% to $9.4 million in 2025, then retreated by 3.47% to $9.1 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $9.1 million (Q1 2026), $9.4 million (Q4 2025), and $9.9 million (Q3 2025), per Business Quant data.